Viewing data from:

EVOTAZ

NDA

ATAZANAVIR SULFATE; COBICISTAT | N206353 | BRISTOL MYERS SQUIBB CO

1 strength2 unique patents0 unique exclusivities

Patent Timeline

2 unique patents by expiration date

Active (2)Today

2027

2028

2029

2030

2031

2032

2033

Today

8148374

Sep. 3, 2029

10039718

Oct. 6, 2032

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 1 NDC

Highest NADAC/Unit

$51.98

per ea

Lowest NADAC/Unit

$51.98

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00003364111EVOTAZ 300 MG-150 MG TABLET	$51.98	EA	Brand	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (1 FSS, 1 Big4)

Lowest Price

$1041.40

Highest Price

$1613.54

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00003-3641-11EVOTAZ 300MG/150MG CAP	$1613.54	FSS	Bristol-Myers Squibb Company	04/30/2029
00003-3641-11EVOTAZ 300MG/150MG CAP	$1041.40	Big4	Bristol-Myers Squibb Company	04/30/2029

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Evotaz (2024)

Total Spending

$10.2M

Total Claims

6,152

Beneficiaries

690

Avg Cost/Unit

$53.12

Spending Trend

$23.4M(2019)→$19.6M(2020)→$16.8M(2021)→$14.8M(2022)→$12.5M(2023)→$10.2M(2024)

YoY Change:-6.3%

5yr CAGR:-0.8%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

Approval Letters

9 letters from Drugs@FDA

Date	Submission	Document
May 14, 2025	SUPPL -9	View Letter (PDF)
May 15, 2023	SUPPL -8	View Letter (PDF)
Aug 3, 2020	SUPPL -7	View Letter (PDF)
Apr 23, 2020	SUPPL -6	View Letter (PDF)
Apr 23, 2018	SUPPL -5	View Letter (PDF)
Jan 30, 2017	SUPPL -3	View Letter (PDF)
Jul 5, 2016	SUPPL -2	View Letter (PDF)
Jul 24, 2015	SUPPL -1	View Letter (PDF)
Feb 2, 2015	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 300MG BASE;150MG

RLD

2 patents0 exclusivities▴

TABLET;ORAL | Approved: Jan 29, 2015

Patents (2) · 1 use code

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
8148374	Sep 3, 2029	—	Yes	Yes		—
10039718	Oct 6, 2032	—	—	Yes	—	—